Cyclacel Pharmaceuticals jumps on sapacitabine patent news

|About: Cyclacel Pharmaceuticals, Inc. (CYCC)|By:, SA News Editor

Cyclacel Pharmaceuticals (CYCC +7.8%) rallies on heavy volume.

The company says the U.S. Patent Office has "issued two patents extending the exclusivity of sapacitabine."

The first patent covers "methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors," while the second covers "methods of use for sapacitabine for the treatment of AML and MDS." (PR)